Patient population (N = 2482)

  • Aged ≥18 years
  • Confirmed symptomatic proximal DVT or PE
  • Treated for 6 to 12 months with AC therapy without
    having a recurrent event or had completed treatment
    in the AMPLIFY trial, and for whom physicians were
    uncertain about continuing the anticoagulant therapy

Primary efficacy outcome

  • Composite of symptomatic recurrent VTE or all-cause
    death

Primary safety outcome

  • Major bleeding*

Key secondary safety outcome

  • Composite of major or CRNM bleeding†
Apixaban
2.5 mg BID oral (n = 840)
Apixaban
5 mg BID oral (n = 813)
Placebo
BID oral (n = 829)
328 centers
28 countries

Limitations

  • Small sample size
  • Randomized controlled trials include
    patients and participating centers that
    may not be entirely representative of the
    real-world setting
R
12 Months